Sheng-Jiun Wu - Johnson & Johnson | 人才画像

基本信息

浏览量：21

职业迁徙

个人简介

Sheng-Jiun Wu currently works at the Janssen Research and Development, LLC, Johnson & Johnson. Sheng-Jiun does research in Biotechnology, Molecular Biology and Structural Biology. Their most recent publication is 'Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality'.

研究兴趣

论文共 58 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplemental Figure S5 from A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

Sheri L. Moores,Mark L. Chiu,Barbara S. Bushey,Kristen Chevalier,Leopoldo Luistro,Keri Dorn,Randall J. Brezski,Peter Haytko,Thomas Kelly,Sheng-Jiun Wu,Pauline L. Martin, Joost Neijssen,Paul W.H.I. Parren,Janine Schuurman,Ricardo M. Attar,Sylvie Laquerre,Matthew V. Lorenzi,G. Mark Anderson

crossref（2023）

引用0浏览0引用

“Stapling” Scfv for Multispecific Biotherapeutics of Superior Properties

Lauren E. Boucher,Elisabeth Geyer Prinslow,Michael Feldkamp,Fang Yi,Rupesh Nanjunda,Sheng-Jiun Wu, Tun Liu,Eilyn R. Lacy,Steven Jacobs,Natalia Kozlyuk, Brian Del Rosario,Bingyuan Wu,Patricia Aquino, Robert C. Davidson, Samantha Heyne, Nicholas Mazzanti, James Testa,Michael D. Diem, Elsa Gorre,Andrew Mahan,Hirsh Nanda,Harsha P. Gunawardena,Alexis Gervais,Anthony A. Armstrong,Alexey Teplyakov,Chichi Huang,Adam Zwolak,Partha Chowdhury, Cheung,Jinquan Luo

mAbs（2023）

引用2浏览0WOS引用

Supplemental Figure S4 from A Novel Bispecific Antibody Targeting EGFR and Cmet is Effective Against EGFR Inhibitor–Resistant Lung Tumors

crossref（2023）

引用0浏览0引用

Supplemental Figure S3 from A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

crossref（2023）

引用0浏览0引用

Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma

Anna Kuchnio,Danlin Yang,Nele Vloemans, Cassandra Lowenstein,Ivo Cornelissen, Ricardo Amorim, Chao Han, Siddharth Sukumaran,Lut Janssen, Toon Suls,Mariette Bekkers,Elena Lasorsa, Lorena Fontana, Nicole Medeiros,Bingyuan Wu, Jun Chen,Michael Feldkamp,Sheng-Jiun Wu, Habtom Habte, John Krayer

Bloodno. Supplement 1 (2022): 3105-3106

引用3浏览0引用

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

Nikki DeAngelis,Catherine Ferrante,Gordon Powers,Jocelyn Sendecki,Bethany Mattson,Darlene Pizutti,Kathryn Packman,Weirong Wang,Kevin Trouba,Rupesh Nanjunda,John Wheeler, Ray Brittingham,Sheng-Jiun Wu,Jinquan Luo,Matthew V. Lorenzi,Raluca I. Verona

Cancer Chemother Pharmacol（2022）

引用5浏览0WOS引用

Abstract 5662: JNJ-67571244: A Novel Anti-Cd33 C2 Domain Binding Bispecific Antibody with Potent T Cell Redirection Activity

Priyanka Nair-Gupta, M. Diem, D. Reeves, Weirong Wang, R. Schulingkamp,Katrin Sproesser,Bethany Mattson, B. Heidrich, J. Joseph,J. Sendecki,Brad Foulk, Gerald C. Chu, D. Fink, Q. Jiao,Sheng‐Jiun Wu,K. Packman, Y. Elsayed, R. Attar, F. Gaudet

Immunology (2020)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn